Dr. Qu Zhican Attends World ADC Conference, Unveils Nanolattix's Innovative "ADC + RDC Theranostic Integration" Strategy

From November 3rd to 6th, 2025, the 16th World ADC Conference (World ADC San Diego 2025) was held in San Diego, USA. Over 1,500 experts and scholars from leading global pharmaceutical companies and research institutions, including AstraZeneca, Pfizer, and Genentech, attended the event to discuss the latest scientific advancements and industrialization trends in the field of Antibody-Drug Conjugates (ADCs).

Nanolattix was invited to participate and presented its latest research findings in the conference's "Translational Medicine" session. The presentation showcased early clinical data for T320, an innovative ADC drug targeting Tissue Factor (TF), and outlined an innovative strategy centered on "ADC + RDC Theranostic Integration," focusing on addressing the two major challenges in cancer treatment: tumor heterogeneity and drug resistance.

Dr. Qu Zhican, Chairman and Chief Scientific Officer of Nanolattix, delivered a keynote speech at the conference. She systematically elaborated on the overall progress of the innovative TF-targeting ADC drug T320, from preclinical research to clinical development, and introduced the company's innovative ADC strategies for overcoming tumor drug resistance.

Currently, T320 is undergoing simultaneous Phase I/II clinical studies in China, the US, and Australia. Preclinical data indicates that the drug demonstrates significant anti-tumor activity in various solid tumor models, with tumor inhibition rates exceeding 90%, and shows outstanding performance regarding ocular toxicity and safety window. Early clinical results are also noteworthy: a 52-year-old patient (S01004) with Stage IV cervical cancer, who had failed multiple prior lines of therapy, achieved stable disease control after receiving T320 treatment, suggesting T320's potential clinical value in refractory solid tumors.

In addition to the keynote speech, Nanolattix also presented its globally leading ADC+RDC theranostic integration strategy via an academic poster. This system, based on the core concept of "what you see is what you treat," utilizes RDCs for lesion visualization and drug distribution verification, followed by precise eradication using ADCs or therapeutic RDCs, truly advancing from "precision therapy" to "integrated precision diagnosis and treatment."

Currently, the combined exploration of RDCs and ADCs remains in its early stages globally. Nanolattix is at the forefront of the industry, having been the first to propose and systematically develop a forward-looking strategy combining RDCs and ADCs. The company has proposed a synergistic "dual-killing" mechanism for ADCs and RDCs: ADCs rely on the high specificity of antibodies to precisely deliver cytotoxic payloads to tumor cells, achieving "point-to-point" elimination; RDCs, through radionuclides releasing radiation, generate a crossfire effect, killing surrounding tumor cells with low or no expression of the target antigen. This combined strategy of "precision killing + broad-spectrum clearance" is expected to significantly reduce the risk of drug resistance and recurrence.

Leveraging its BioLattix technology platform, Nanolattix has built a globally competitive pipeline of ADC and RDC candidates. Among them, T320, targeting TF, is the company's first ADC to enter global clinical stages. It shares the same antibody with the RDC candidate RT01, enabling diagnostic and therapeutic synergy and constituting the world's first "ADC + RDC shared antibody" combination. Simultaneously, the company is advancing two globally innovative drug candidates: the bispecific B836-ADC and RB02-RDC, further expanding therapeutic coverage.

Dr. Qu Zhican stated, "The World ADC Conference is a vital platform for global innovative drug R&D. Sharing the positive progress of T320 and our explorations in theranostic integration with international peers is a significant opportunity for Chinese innovative pharmaceutical companies. Moving forward, Nanolattix will continue to promote synergistic innovation across both the ADC and RDC platforms to bring patients more precise and effective treatment options."

Nanolattix is a biopharmaceutical company focused on dual-track innovation in Antibody-Drug Conjugates (ADCs) and Radiopharmaceutical Drug Conjugates (RDCs), committed to advancing the development of globally competitive integrated cancer theranostics.